IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Paramesu Biotech IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ [●] Cr. The company is based in Hyderabad and caters to Agro sector. Pantomath Capital Advisors is the merchant banker of Paramesu Biotech IPO. It is a MainBoard Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 7th November 2024.
Paramesu Biotech IPO posted revenues of ₹ 818.78 crores and PAT of ₹ 53.70 crores in FY25 on annualised basis.
Revenue:
₹ 81.52 Cr.
EBITDA Margin:
12.34
% 
Net Worth: ₹ 20.01 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Financial results of Paramesu Biotech IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Sep-24 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 47.94 | 43.97 | 31.92 | 23.89 | |
| Net Worth | 20.01 | 17.31 | 13.30 | 10.09 | |
| Total Debt | 21.61 | 20.58 | 14.06 | 8.20 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
40.76
81.52 |
62.78 | 62.39 | 49.49 | |
EBITDA
EBITDA on annualised basis |
5.03
10.06 |
7.65 | 5.67 | 5.97 | |
PAT
PAT on annualised basis |
2.70
5.40 |
4.02 | 3.25 | 3.40 | |
Paramesu Biotech IPO PAT Margin is 6.62 % , ROCE (Return on Capital Employed) is 10.74 % as per latest financial. The below table shows Paramesu Biotech IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Sep-24 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| EBITDA Margin (%) | 12.34 | 12.19 | 9.09 | 12.06 |
| PAT Margin (%) | 6.62 | 6.40 | 5.21 | 6.87 |
| EPS (₹) | 1.02 | 1.54 | 1.24 | 1.29 |
| ROE (%) | 13.49 | 23.22 | 24.44 | 33.70 |
| ROCE (%) | 10.74 | 18.13 | 18.71 | 29.78 |
| ROA (%) | 5.63 | 9.14 | 10.18 | 14.23 |
| Debt to Equity | 1.08 | 1.19 | 1.06 | 0.81 |
The market Capitalisation of Paramesu Biotech IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Paramesu Biotech IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Paramesu Biotech IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Paramesu Biotech IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Paramesu Biotech IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Paramesu Biotech IPO reported revenue of ₹ 818.78 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Paramesu Biotech IPO provide insights into sales growth, market demand, and business scalability.
Paramesu Biotech recorded an EBITDA of ₹ 10.06 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Paramesu Biotech Profit After Tax (PAT) is ₹ 5.40 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 81.52 Cr.
EBITDA Margin:
12.34
%
Net Worth: ₹ 20.01 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Paramesu Biotech operates in Agro and . The Issue is listed on BSE,NSE in May, 2025. Paramesu Biotech IPO size was with Issue price of .
Merchant Banker(s) of Paramesu Biotech IPO: Pantomath Capital Advisors Private Limited
Paramesu Biotech IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Paramesu Biotech IPO listed at a listing price of against the offer price of .
The current market price of Paramesu Biotech is .
Why Us?
